I-Aspect Biosystems ibhengeze intsebenziswano kunye ne-JDRF, eyona ndlela iphambili yophando lwehlabathi lwe-1 yeswekile (T1D) kunye nombutho wokukhuthaza.
Ubambiswano lwe-JDRF-Aspect luxhasa ugxininiso lwe-Aspect ekuphuhliseni i-bioengineered tissue therapeutic yohlobo lwe-1 yeswekile eya kubonelela ngokuzimela kwe-insulin kunye nokulawula iswekile yegazi ngaphandle kwesidingo sokunyanzeliswa kwe-immune engapheliyo. Ukongeza kwinkxaso-mali, i-JDRF ikwanegalelo lenkxaso yeqhinga ngobuchwephesha bayo obunzulu kunye nothungelwano olukhulu kwinkalo yesifo seswekile.
Umba wokusebenzisa itekhnoloji ye-bioprinting yobunini, iiseli zonyango, kunye nesayensi yezixhobo ukwenza umbhobho wonyango olusekwe kwiseli oluthatha indawo okanye lulungise imisebenzi yelungu eyonakeleyo. Olu nyango lwenziwe ngokufanelekileyo ukuba lusebenze ngokwebhayoloji, lukhuseleke kwi-immune, kwaye lulungele ukufakelwa kotyando ukunyanga izifo ezifana nohlobo loku-1 lweswekile.
"Kwiminyaka engaphezu kwe-20, i-JDRF ibe yinkokeli yophando lwe-cell-based tissue therapy yesifo sikashukela sohlobo lwe-1," watsho u-Esther Latres, uSekela Mongameli woPhando kwi-JDRF. "Obu budlelwane benkxaso-mali kunye ne-Aspect Biosystems iya kuxhasa kwaye iqhubeke nenkqubela phambili yesayensi kwicandelo kwaye ngokungathandabuzekiyo isisondeze ekufumaneni unyango."
"Kunye ne-JDRF, silungelelaniswe kwinjongo yokuphuhlisa unyango olunyanga izigidi zezigulane kwihlabathi jikelele ezichatshazelwa luhlobo lwesifo seswekile," utshilo uTamer Mohamed, i-CEO kwi-Aspect Biosystems. "Olu budlelwane luza kunceda ukuqhubela phambili inkqubo yethu yezicubu ze-pancreatic kwaye isizise inyathelo elikufutshane nezilingo zabantu."
